These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 33193442)

  • 1. How Does Complement Affect Hematological Malignancies: From Basic Mechanisms to Clinical Application.
    Luo S; Wang M; Wang H; Hu D; Zipfel PF; Hu Y
    Front Immunol; 2020; 11():593610. PubMed ID: 33193442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement as a Biological Tool to Control Tumor Growth.
    Macor P; Capolla S; Tedesco F
    Front Immunol; 2018; 9():2203. PubMed ID: 30319647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The complement system in cancer: Ambivalence between tumour destruction and promotion.
    Mamidi S; Höne S; Kirschfink M
    Immunobiology; 2017 Jan; 222(1):45-54. PubMed ID: 26686908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement System: a Neglected Pathway in Immunotherapy.
    Bordron A; Bagacean C; Tempescul A; Berthou C; Bettacchioli E; Hillion S; Renaudineau Y
    Clin Rev Allergy Immunol; 2020 Apr; 58(2):155-171. PubMed ID: 31144209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reprogramming Tumor-Immune Cell Interface in Solid and Hematological Malignancies to Enhance Response to Therapy.
    Di Martino MT; Zazzeroni F; Donadelli M; Chiodoni C; Caraglia M; Scotlandi K; Meschini S; Leonetti C
    J Exp Clin Cancer Res; 2018 Mar; 37(1):48. PubMed ID: 29506548
    [No Abstract]   [Full Text] [Related]  

  • 6. Disturbances in complement recognition and control in human disease - An editorial to a special issue on "Complement Regulation".
    Meri S
    Semin Immunol; 2019 Oct; 45():101345. PubMed ID: 31703833
    [No Abstract]   [Full Text] [Related]  

  • 7. Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
    Ye B; Stary CM; Gao Q; Wang Q; Zeng Z; Jian Z; Gu L; Xiong X
    J Immunol Res; 2017; 2017():5210459. PubMed ID: 28116322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The eye as a complement dysregulation hotspot.
    Clark SJ; Bishop PN
    Semin Immunopathol; 2018 Jan; 40(1):65-74. PubMed ID: 28948331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors.
    Charmsaz S; Scott AM; Boyd AW
    Exp Hematol; 2017 Oct; 54():31-39. PubMed ID: 28751189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement activation and regulation in rheumatic disease.
    Dijkstra DJ; Joeloemsingh JV; Bajema IM; Trouw LA
    Semin Immunol; 2019 Oct; 45():101339. PubMed ID: 31718864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric Oxide in Hematological Cancers: Partner or Rival?
    Vivarelli S; Falzone L; Basile MS; Candido S; Libra M
    Antioxid Redox Signal; 2021 Feb; 34(5):383-401. PubMed ID: 32027171
    [No Abstract]   [Full Text] [Related]  

  • 12. Complement activation, a threat to pregnancy.
    Girardi G
    Semin Immunopathol; 2018 Jan; 40(1):103-111. PubMed ID: 28900713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dichotomy of complement system: Tumorigenesis or destruction.
    Sinha A; Singh V; Tandon R; Mohan Srivastava L
    Immunol Lett; 2020 Jul; 223():89-96. PubMed ID: 32333965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
    Tsirigotis P; Savani BN; Nagler A
    Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting complement-mediated immunoregulation for cancer immunotherapy.
    Kolev M; Markiewski MM
    Semin Immunol; 2018 Jun; 37():85-97. PubMed ID: 29454575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The complement system in systemic autoimmune disease.
    Chen M; Daha MR; Kallenberg CG
    J Autoimmun; 2010 May; 34(3):J276-86. PubMed ID: 20005073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complement System in Alcohol-Associated Liver Disease.
    Santiesteban-Lores LE; Carneiro MC; Isaac L; Bavia L
    Immunol Lett; 2021 Aug; 236():37-50. PubMed ID: 34111475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The complement system as a target in cancer immunotherapy.
    Merle NS; Roumenina LT
    Eur J Immunol; 2024 Oct; 54(10):e2350820. PubMed ID: 38996361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of the complement system and immunological tolerance in pregnancy.
    Teirilä L; Heikkinen-Eloranta J; Kotimaa J; Meri S; Lokki AI
    Semin Immunol; 2019 Oct; 45():101337. PubMed ID: 31757607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement System in Cutaneous Squamous Cell Carcinoma.
    Riihilä P; Nissinen L; Knuutila J; Rahmati Nezhad P; Viiklepp K; Kähäri VM
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31331124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.